We discuss the case of a 38-year-old 3 Sarcoidosis is most often associated with the lungs, but the disease can manifest itself in any tissue. Cardiac involvement was not described until 1929. 4,5 In recent times, cardiac manifestations have been understood to play a greater role in sarcoidosis morbidity than previously thought. In this report, we present a case of primary cardiac sarcoidosis that was successfully treated with a hybrid pharmacologic, surgical, and catheterbased intervention.
Case ReportA 38-year-old black man presented at our clinic for evaluation of his first syncopal episode and atrial fibrillation (AF), this last accompanied by a rapid ventricular rate that was refractory to diltiazem, metoprolol, and digoxin therapy. The patient reported shortness of breath, intermittent palpitations, and chest pain. His medical history was significant for hypertension, obstructive sleep apnea, and diabetes mellitus type 2. Further, he had an implantable cardioverter-defibrillator to prevent sudden cardiac death due to his congestive heart failure (left ventricular ejection fraction [LVEF], 0.20-0.25, at the time of implantation). No electrocardiogram before the onset of AF was available at the time of his presentation to our clinic.The patient's initial evaluation included a transesophageal echocardiogram (TEE) that suggested left atrial thrombus with a preserved LVEF of 0.50 to 0.55. Rigorous anticoagulation therapy with a target international normalized ratio (INR) of 3.0 maintained for 6 months was apparently unsuccessful in dissolving the atrial thrombus. The patient had a high risk for thrombus embolization and for further clot formation from his newly documented atrial flutter. We determined that he would benefit from a hybrid procedure incorporating surgical excision of the atrial appendage and atrial mass, with subsequent catheter-based ablation targeting the atypical flutter. The atrial flutter and AF were the only arrhythmias identified by means of rhythm monitoring.